MX2018010445A - Anticuerpos especificos del receptor de poliovirus humano (rvp). - Google Patents

Anticuerpos especificos del receptor de poliovirus humano (rvp).

Info

Publication number
MX2018010445A
MX2018010445A MX2018010445A MX2018010445A MX2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A MX 2018010445 A MX2018010445 A MX 2018010445A
Authority
MX
Mexico
Prior art keywords
pvr
antibodies specific
poliovirus receptor
human poliovirus
receptor
Prior art date
Application number
MX2018010445A
Other languages
English (en)
Spanish (es)
Inventor
Mandelboim Ofer
S Kaynan Noa
Tsukerman Pinchas
Jonjic Stipan
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of MX2018010445A publication Critical patent/MX2018010445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
MX2018010445A 2016-03-01 2017-02-28 Anticuerpos especificos del receptor de poliovirus humano (rvp). MX2018010445A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301727P 2016-03-01 2016-03-01
US201662364924P 2016-07-21 2016-07-21
PCT/IL2017/050256 WO2017149538A1 (en) 2016-03-01 2017-02-28 Antibodies specific to human poliovirus receptor (pvr)

Publications (1)

Publication Number Publication Date
MX2018010445A true MX2018010445A (es) 2019-10-17

Family

ID=58410405

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010445A MX2018010445A (es) 2016-03-01 2017-02-28 Anticuerpos especificos del receptor de poliovirus humano (rvp).
MX2022014867A MX2022014867A (es) 2016-03-01 2018-08-29 Anticuerpos especificos del receptor de poliovirus humano (rvp).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014867A MX2022014867A (es) 2016-03-01 2018-08-29 Anticuerpos especificos del receptor de poliovirus humano (rvp).

Country Status (15)

Country Link
US (3) US10906987B2 (enExample)
EP (2) EP3423495B1 (enExample)
JP (1) JP6966176B2 (enExample)
KR (2) KR20250065434A (enExample)
CN (1) CN109071666B (enExample)
AU (2) AU2017228055B2 (enExample)
BR (1) BR112018067522A2 (enExample)
CA (1) CA3015619A1 (enExample)
CO (1) CO2018010538A2 (enExample)
ES (1) ES2903280T3 (enExample)
IL (2) IL261200B2 (enExample)
MX (2) MX2018010445A (enExample)
RU (1) RU2756275C2 (enExample)
SG (1) SG11201807437XA (enExample)
WO (1) WO2017149538A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098130B1 (en) 2015-08-03 2021-08-24 Tasrif Pharmaceutical, LLC Antibodies and antibody fragments against the CD155 receptor and methods of use thereof
EP3423495B1 (en) 2016-03-01 2021-10-20 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
WO2019102456A1 (en) 2017-11-27 2019-05-31 University Of Rijeka Faculty Of Medicine Immunotoxins for treating cancer
KR20250173584A (ko) 2018-05-09 2025-12-10 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 넥틴4에 특이적인 항체
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
EP4659757A3 (en) 2018-08-30 2026-01-14 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
CN120267819A (zh) 2018-08-30 2025-07-08 免疫生物公司 治疗老年化相关病症的方法
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
EP3908372A1 (en) * 2019-01-13 2021-11-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human nectin-2
EP3987010A1 (en) 2019-06-21 2022-04-27 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
KR20220082007A (ko) * 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
KR102370915B1 (ko) 2019-10-22 2022-03-08 단국대학교 천안캠퍼스 산학협력단 폴리오바이러스를 검출하기 위한 등온증폭 반응용 프라이머 세트 및 이의 용도
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CA3181417A1 (en) 2020-04-29 2021-11-04 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
WO2021247604A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CN112538108B (zh) * 2020-12-24 2022-06-28 郑州大学 高亲和pvr突变体
AU2021460932A1 (en) * 2021-08-20 2024-03-07 Tasrif Pharmaceutical, LLC Antibodies and antigen binding fragments against cd155 methods of use thereof
CN114005538B (zh) * 2021-11-30 2025-10-28 中国医科大学附属第一医院 Nectin家族和类nectin分子在低级别胶质瘤预后模型中的应用
AU2023228683B2 (en) 2022-03-02 2025-12-04 Immunitybio, Inc. Method of treating pancreatic cancer
KR20240144422A (ko) 2022-03-15 2024-10-02 컴퓨젠 엘티디. 암 치료의 단독치료법 및 병용치료법에서 il-18bp 길항제 항체 및 이의 용도
AU2023331612A1 (en) 2022-09-04 2025-02-13 Nectin Therapeutics Ltd. Drug conjugates of humanized anti pvr antibodies
CN116284395B (zh) * 2022-12-12 2024-11-08 合肥天港免疫药物有限公司 抗cd155的抗体及其应用
WO2024233945A1 (en) * 2023-05-10 2024-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy of polio virus receptor inhibitors and fucose
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
KR102669477B1 (ko) * 2023-09-04 2024-06-10 재단법인 아산사회복지재단 신규 항-pvr 항체 또는 이의 항원 결합 단편, 및 이의 용도
CN118359711B (zh) * 2024-06-20 2024-10-15 华淞(上海)生物医药科技有限公司 一种抗脊髓灰质炎病毒1型抗体及其制备方法和用途

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
CZ287296B6 (en) 1992-01-23 2000-10-11 Merck Patent Gmbh Antibody construct and structural kit for selective preparation thereof
ATE348175T1 (de) 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0721350A4 (en) 1993-07-30 1999-08-11 Univ Jefferson INTRACELLULAR IMMUNIZATION
US6294353B1 (en) 1994-10-20 2001-09-25 Morphosys Ag Targeted hetero-association of recombinant proteins to multi-functional complexes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE274064T1 (de) 1995-05-23 2004-09-15 Morphosys Ag Multimere proteine
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
US6518033B1 (en) * 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
EP1481993A1 (en) * 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ATE515512T1 (de) 2005-05-12 2011-07-15 Zymogenetics Inc Zusammensetzungen und verfahren zur modulierung von immunreaktionen
EP2311876A3 (en) 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
KR101624587B1 (ko) 2005-12-20 2016-05-26 에스비아이 바이오테크 가부시키가이샤 항-ｉｌｔ7 항체
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
JP2010524846A (ja) 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体
PL3208612T3 (pl) 2008-04-09 2020-03-31 Genentech, Inc. Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
JP5686361B2 (ja) * 2010-01-28 2015-03-18 国立大学法人 筑波大学 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
RU2592672C9 (ru) 2010-12-08 2016-11-27 СтемСентРкс, Инк. Новые модуляторы и способы их применения
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
PL2800196T3 (pl) 2011-12-27 2019-05-31 Lg Chemical Ltd Litowa bateria akumulatorowa i sposób jej wytwarzania
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BONDING AGENT FOR MODULATING THE HIPPO PATH AND USES THEREOF
TW201439115A (zh) 2012-12-04 2014-10-16 Oncomed Pharm Inc 使用結合劑之免疫治療
ME03394B (me) 2013-02-22 2020-01-20 Medimmune Ltd Antidllз-antitelo-pbd konjugati i nihovа upotreba
MX384142B (es) 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
WO2015031693A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Engineered anti-dll3 conjugates and methods of use
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
EP3119211A1 (en) 2014-03-18 2017-01-25 Gokmen, Vural A solution for extending shelf life of ready-to-eat fresh fruits and/or vegetables and an application method thereof
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3423495B1 (en) 2016-03-01 2021-10-20 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)

Also Published As

Publication number Publication date
KR102812377B1 (ko) 2025-05-23
AU2017228055B2 (en) 2024-04-04
US10906987B2 (en) 2021-02-02
JP6966176B2 (ja) 2021-11-10
US20240018257A1 (en) 2024-01-18
WO2017149538A1 (en) 2017-09-08
KR20250065434A (ko) 2025-05-12
IL296874A (en) 2022-11-01
ES2903280T3 (es) 2022-03-31
CN109071666B (zh) 2022-06-28
KR20180133399A (ko) 2018-12-14
BR112018067522A2 (pt) 2019-02-05
NZ745564A (en) 2024-12-20
SG11201807437XA (en) 2018-09-27
EP3423495A1 (en) 2019-01-09
JP2019511212A (ja) 2019-04-25
CO2018010538A2 (es) 2018-12-14
MX2022014867A (es) 2023-03-06
EP3423495B1 (en) 2021-10-20
RU2018134065A3 (enExample) 2020-07-20
IL261200B (en) 2022-11-01
CA3015619A1 (en) 2017-09-08
IL261200B2 (en) 2023-03-01
RU2018134065A (ru) 2020-04-01
CN109071666A (zh) 2018-12-21
IL261200A (en) 2018-10-31
AU2024201912A1 (en) 2024-04-11
AU2017228055A1 (en) 2018-09-20
RU2756275C2 (ru) 2021-09-29
US20210115150A1 (en) 2021-04-22
EP4043492A1 (en) 2022-08-17
US20200040092A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
MX2018010445A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
BR112016014731A2 (pt) Anticorpos anti-baff
CL2018000378A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
MX2016010856A (es) Metodo.
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
CO2017006740A2 (es) Anticuerpos anti–cd79b
MX2017001599A (es) Anticuerpos novedosos y sus usos.
MX2017001597A (es) Anticuerpos anti-pd-l1.
ECSP17012781A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
BR112017011914A2 (pt) ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
AR102649A1 (es) Anticuerpos anti-cadherina-p y conjugados anticuerpos-fármacos
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CL2019003557A1 (es) Anticuerpos anti-trkb.
BR112019020412A2 (pt) composições e métodos para detectar câncer de pulmão
AR113854A1 (es) Anticuerpos anti-cxcr5, composiciones y usos de los mismos
AR099899A1 (es) Anticuerpos y fragmentos anti-vista
BR112017020894A2 (pt) imunoreceptores específicos claudina-18.2 e epítopos de células t